Pharma

Catalent Inc <CTLT.N>: Profits of 69 cents per share anticipated for fourth quarter

  • February 03, 2023 06:11 AM PST | Reuters
 Catalent Inc <CTLT.N>: Profits of 69 cents per share anticipated for fourth quarter

3 February 2023 02:11 p.m. All figures in US dollars. Catalent Inc is expected to show a decrease in its fourth quarter earnings to 69 cents​ per share according to the mean Refinitiv estimate from

Read More...
Immunovant Reports Cash Balance Of About $433 Mln As Of December 31

Immunovant Reports Cash Balance Of About $433 Mln As Of December 31

  • February 03, 2023 04:49 AM PST | Reuters

Feb 3 (Reuters) - Immunovant Inc: * IMMUNOVANT REPORTS FINANCIAL RESULTS AND RECENT BUSINESS UPDATES FOR THE QUARTER ENDED DECEMBER 31, 2022 * IMMUNOVANT INC - CASH BALANCE OF ABOUT $433 MILLION AS OF

Read More...
Twist Bioscience Reports Fiscal First Quarter 2023 Results

Twist Bioscience Reports Fiscal First Quarter 2023 Results

  • February 03, 2023 04:47 AM PST | Reuters

Feb 3 (Reuters) - Twist Bioscience Corp: * TWIST BIOSCIENCE REPORTS FISCAL FIRST QUARTER 2023 FINANCIAL RESULTS * Q1 EARNINGS PER SHARE VIEW $-1.13, REVENUE VIEW $54.1 MILLION -- REFINITIV IBES DATA *

Read More...
Immunovant Inc <IMVT.O>: Losses of 49  cents announced for third quarter

Immunovant Inc <IMVT.O>: Losses of 49  cents announced for third quarter

  • February 03, 2023 04:46 AM PST | Reuters

3 February 2023 12:46 p.m. ​All figures in US dollars. The loss announced by Immunovant Inc in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -

Read More...
Immunovant Inc reports results for the quarter ended in December - Earnings Summary

Immunovant Inc reports results for the quarter ended in December - Earnings Summary

  • February 03, 2023 04:46 AM PST | Reuters

* Immunovant Inc reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended in December. The mean expectation of eight analysts for the quarter was for a loss of 39 cents per

Read More...
Oragenics Regains Compliance With NYSE American

Oragenics Regains Compliance With NYSE American

  • February 03, 2023 04:45 AM PST | Reuters

Feb 3 (Reuters) - Oragenics Inc: * ORAGENICS, INC. REGAINS COMPLIANCE WITH NYSE AMERICAN Source text for Eikon: Further company coverage:

Read More...
Vyant Bio Inc Says Under Cash Preservation Plan Of Jan 31,  Co Sees To Incur About $1.4 Mln For Employee Termination-Related Costs In Q1, Q2 Of 2023

Vyant Bio Inc Says Under Cash Preservation Plan Of Jan 31, Co Sees To Incur About $1.4 Mln For Employee Termination-Related Costs In Q1, Q2 Of 2023

  • February 03, 2023 04:42 AM PST | Reuters

Feb 3 (Reuters) - Vyant Bio Inc: * VYANT BIO INC - UNDER CASH PRESERVATION PLAN OF JAN 31, CO SEES TO INCUR ABOUT $1.4 MILLION FOR EMPLOYEE TERMINATION-RELATED COSTS IN Q1 AND Q2 OF 2023 * VYANT BIO

Read More...
Merck Says Keytruda Plus Chemotherapy Met Primary Endpoint Of Progression-Free Survival As First-Line Therapy For Advanced Or Recurrent Endometrial Carcinoma

Merck Says Keytruda Plus Chemotherapy Met Primary Endpoint Of Progression-Free Survival As First-Line Therapy For Advanced Or Recurrent Endometrial Carcinoma

  • February 03, 2023 04:40 AM PST | Reuters

Feb 3 (Reuters) - Merck &amp; Co Inc: * MERCK’S KEYTRUDA® (PEMBROLIZUMAB) PLUS CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE THERAPY FOR ADVANCED OR RECURRENT

Read More...
Regeneron Sees 2023 Capital Expenditures Of $825-$950 Mln

Regeneron Sees 2023 Capital Expenditures Of $825-$950 Mln

  • February 03, 2023 04:38 AM PST | Reuters

Feb 3 (Reuters) - Regeneron Pharmaceuticals Inc : * REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS * REGENERON PHARMACEUTICALS - SUPPLEMENTAL BLA FOR EYLEA TO

Read More...
Neurocrine Biosciences Inc <NBIX.O>: Profits of $1.14 per share anticipated for fourth quarter

Neurocrine Biosciences Inc <NBIX.O>: Profits of $1.14 per share anticipated for fourth quarter

  • February 03, 2023 04:33 AM PST | Reuters

3 February 2023 12:33 p.m. All figures in US dollars. Neurocrine Biosciences Inc is expected to show an increase in its fourth quarter earnings to $1.14​ per share according to the mean Refinitiv

Read More...
Neurocrine Biosciences Inc expected to post earnings of $1.14 a share - Earnings Preview

Neurocrine Biosciences Inc expected to post earnings of $1.14 a share - Earnings Preview

  • February 03, 2023 04:32 AM PST | Reuters

* Neurocrine Biosciences Inc is expected to show a rise in quarterly revenue when it reports results on February 6. * The San Diego California-based company is expected to report a 31.1% increase in

Read More...